Drug delivery of oral anti-cancer fluoropyrimidine agents

References

• Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663–666.
   PubMed Web of Science ®Google Scholar
• Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep. 1964;35:1–111.
   PubMedGoogle Scholar
• Wilkoff LJ, Wilcox WS, Burdeshaw JA, et al. Effect of antimetabolites on kinetic behavior of proliferating cultured L1210 leukemia cells. J Natl Cancer Inst. 1967;39:965–975.
   PubMed Web of Science ®Google Scholar
• Miura K, Shirasaka T, Yamaue H, et al. S-1 as a core anticancer fluoropyrimidine agent. Expert Opin Drug Deliv. 2012;9(3):273–286.
   PubMed Web of Science ®Google Scholar
• Rutman RJ, Cantarow A, Paschkis KE. The catabolism of uracil in vivo and in vitro. J Biol Chem. 1954;210:321–329.
   PubMed Web of Science ®Google Scholar
• Handschumacher RE, Welch AD. Microbial studies of 6-azauracil, an antagonist of uracil. Cancer Res. 1956;16:965–969.
   PubMed Web of Science ®Google Scholar
• Heidelberger C, Griesbach L, Montag BJ, et al. Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. Cancer Res. 1958;18:305–317.
   PubMed Web of Science ®Google Scholar
• Chaudhuri NK, Montag BJ, Heidelberger C. Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo. Cancer Res. 1958;18:318–328.
   PubMed Web of Science ®Google Scholar
• Gotto AM, Belkhode ML, Touster O. Stimulatory effects of inosine and deoxyinosine on the incorporation of uracil-2-14-C, 5-fluorouracil-2-14-C, and 5-bromouracil-2-14-C into nucleic acids by Ehrlich ascites tumor cells in vitro. Cancer Res. 1969;29:807–811.
   PubMed Web of Science ®Google Scholar
• Hartmann KU, Heidelberger C. Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. J Biol Chem. 1961;236:3006–3013.
   PubMed Web of Science ®Google Scholar
• Spears CP, Shahinian AH, Moran RG, et al. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res. 1982;42:450–456.
   PubMed Web of Science ®Google Scholar
• Danenberg PV, Gustavsson B, Johnston P, et al. Folates as adjuvants to anticancer agents: chemical rationale and mechanism of action. Crit Rev Oncol Hematol. 2016;106:118–131.
   PubMed Web of Science ®Google Scholar
• Chaudhuri NK, Mukherjee KL, Heidelberger C. Studies on fluorinated pyrimidines. VII-the degradative pathway. Biochem. Pharmacol. 1959;1:328–341.
   Web of Science ®Google Scholar
• Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203–2206.
   PubMed Web of Science ®Google Scholar
• Schuetz JD, Wallace HJ, Diasio RB. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity.. Cancer Res. 1984;44:1358–1363.
   PubMed Web of Science ®Google Scholar
• Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2’-deoxyuridine. Cancer Res. 1979;39:2406–2413.
   PubMed Web of Science ®Google Scholar
• Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?. Clin Cancer Res. 2008;14:8–13.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Noordhuis P, Van Kuilenburg AB, et al. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol. 2003;52:1–12.
   PubMed Web of Science ®Google Scholar
• Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol. 1970;23:155–160.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Yada H, Ariyoshi T. Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs. J Toxicol Sci. 2004;29:155–166.
   PubMedGoogle Scholar
• Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol. 1980;30:871–879.
   PubMedGoogle Scholar
• Meta-analysis Group in Cancer, Piedbois P, Rougier P, Buyse M, et al. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301–308.
   PubMed Web of Science ®Google Scholar
• Rosenbaum SE. Basic pharmacokinetics and pharmacodynamics: an integrated textbook and computer simulations. Hoboken (NJ): Wiley-Blackwell; 2012.
   Google Scholar
• Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999;5:2289–2296.
   PubMed Web of Science ®Google Scholar
• Giller SA, Zhuk RA, Lidak M. Analogs of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolites. Article in Russian. Dokl Akad Nauka SSSR. 1967;176:332–335.
   PubMedGoogle Scholar
• Au JL, Sadée W. The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil. Recent Results Cancer Res. 1981;76:100–114.
   PubMedGoogle Scholar
• Au JL, Wu AT, Friedman MA, et al. Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep. 1979;63:343–350.
   PubMedGoogle Scholar
• Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica. 1996;26:395–403.
   PubMed Web of Science ®Google Scholar
• Buroker T, Miller A, Baker L, et al. Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer. Cancer Treat Rep. 1977;61:1579–1580.
   PubMedGoogle Scholar
• Toide H, Akiyoshi H, Minato Y, et al. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann. 1977;68:553–560.
   PubMedGoogle Scholar
• Fujii S, Ikenaka K, Fukushima M, et al. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann. 1978;69:763–772.
   PubMedGoogle Scholar
• Fujii S, Kitano S, Ikenaka K, et al. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann. 1979;70:209–214.
   PubMedGoogle Scholar
• Ho DH, Pazdur R, Covington W, et al. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2’-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res. 1998;4:2085–2088.
   PubMed Web of Science ®Google Scholar
• Poon MA, O’Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 1991;9:1967–1972.
   PubMed Web of Science ®Google Scholar
• Herrmann R. Biochemical modulation of 5-fluorouracil. Cancer Treat Rev. 1990;17(Suppl A):51–55.
   PubMed Web of Science ®Google Scholar
• Ullman B, Lee M, Martin DW Jr, et al. Cytotoxicity of 5-fluoro-2’-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci U S A. 1978;75:980–983.
   PubMed Web of Science ®Google Scholar
• Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. 1981;41:3288–3295.
   PubMed Web of Science ®Google Scholar
• Cao S, Frank C, Shirasaka T, et al. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin Cancer Res. 1995;1:839–845.
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–557.
   PubMed Web of Science ®Google Scholar
• Tatsumi K, Fukushima M, Shirasaka T, et al. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res. 1987;78:748–755.
   PubMedGoogle Scholar
• Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004–4009.
   PubMed Web of Science ®Google Scholar
• Granat P, Creasey WA, Calabresi P, et al. Investigations with 5-azaorotic acid, an inhibitor of the biosynthesis of pyrimidines de novo. Clin Pharmacol Ther. 1965;6:436–447.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ueda Y, Fuji N, et al. Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil. Cancer Chemother Pharmacol. 2006;58:183–188.
   PubMed Web of Science ®Google Scholar
• Cook AF, Holman MJ, Kramer MJ, et al. Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5’-deoxy-5-fluoropyrimidine nucleosides. J Med Chem. 1979;22:1330–1335.
   PubMed Web of Science ®Google Scholar
• Ishitsuka H, Miwa M, Takemoto K, et al. Role of uridine phosphorylase for antitumor activity of 5’-deoxy-5-fluorouridine. Gann. 1980;71:112–123.
   PubMedGoogle Scholar
• Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274–1281.
   PubMed Web of Science ®Google Scholar
• Shimma N, Umeda I, Arasaki M, et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg Med Chem. 2000;8:1697–1706.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 1998;55:1091–1097.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097–4106.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004;90:1190–1197.
   PubMed Web of Science ®Google Scholar
• Saif MW. Capecitabine and hand-foot syndrome.. Expert Opin Drug Saf. 2011;10:159–169.
   PubMed Web of Science ®Google Scholar
• Reigner B, Watanabe T, Schuller J, et al. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol. 2003;52:193–201.
   PubMed Web of Science ®Google Scholar
• Hattori K, Kohchi Y, Oikawa N, et al. Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine. Bioorg Med Chem Lett. 2003;13:867–872.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18:1337–1345.
   PubMed Web of Science ®Google Scholar
• Funaki T, Onodera H, Ogawa K, et al. Simultaneous determination of a new anticancer drug galocitabine and its metabolites in blood by high-performance liquid chromatography. J Pharm Biomed Anal. 1993;11:379–384.
   PubMed Web of Science ®Google Scholar
• Shirao K, Hoff PM, Ohtsu A, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol. 2004;22:3466–3474.
   PubMed Web of Science ®Google Scholar
• Damle B, Ravandi F, Kaul S, et al. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Clin Cancer Res. 2001;7:517–523.
   PubMed Web of Science ®Google Scholar
• Hirata K, Horikoshi N, Aiba K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 1999;5:2000–2005.
   PubMed Web of Science ®Google Scholar
• Hoff PM, Saad ED, Ajani JA, et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res. 2003;9:134–142.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Noordhuis P, Van Groeningen CJ, et al. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res. 2004;10:4072–4076.
   PubMed Web of Science ®Google Scholar
• Judson IR, Beale PJ, Trigo JM, et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs. 1999;17:49–56.
   PubMed Web of Science ®Google Scholar
• Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res. 1998;4:941–948.
   PubMed Web of Science ®Google Scholar
• Hyodo I, Shirao K, Doi T, et al. A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2006;36:410–417.
   PubMed Web of Science ®Google Scholar
• Ebi H, Sigeoka Y, Saeki T, et al. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5’-deoxy-5-fluorouridine (5’-DFUR). Cancer Chemother Pharmacol. 2005;56:205–211.
   PubMed Web of Science ®Google Scholar
• Milano G, Ferrero JM, François E. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer. 2004;91(4):613–617.
   PubMed Web of Science ®Google Scholar
• Baccanari DP, Davis ST, Knick VC, et al. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci U S A. 1993;90:11064–11068.
   PubMed Web of Science ®Google Scholar
• Tatsumi K, Yamauchi T, Kiyono K, et al. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. J Biochem. 1993;114:912–918.
   PubMed Web of Science ®Google Scholar
• Fujii S, Fukushima M, Shimamoto Y, et al. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn J Cancer Res. 1989;80:173–181.
   PubMedGoogle Scholar
• Endo M, Miwa M, Eda H, et al. Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003;106:799–805.
   PubMed Web of Science ®Google Scholar
• Bellibas SE, Patel I, Chamorey E, et al. Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. Clin Cancer Res. 2004;10:2327–2335.
   PubMed Web of Science ®Google Scholar
• Saito K, Nagashima H, Noguchi K, et al. First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers. Cancer Chemother Pharmacol. 2014;73:577–583.
   PubMed Web of Science ®Google Scholar
• Crout JR. Fixed combination prescription drugs: FDA policy. J Clin Pharmacol. 1974;14:249–254.
   PubMed Web of Science ®Google Scholar
• https://www.gpo.gov/fdsys/pkg/CFR-2012-title21-vol1/pdf/CFR-2012-title21-vol1-part3.pdf
   Google Scholar
• http://www.fda.gov/CombinationProducts/AboutCombinationProducts/ucm118332.htm
   Google Scholar
• https://www.gpo.gov/fdsys/pkg/CFR-2010-title21-vol1/pdf/CFR-2010-title21-vol1-sec3-4.pdf
   Google Scholar
• Shorter E. The liberal state and the rogue agency: FDA’s regulation of drugs for mood disorders, 1950s–1970s. Int J Law Psychiatry. 2008;31:126–135.
   PubMed Web of Science ®Google Scholar
• Levinson AD. Cancer therapy reform. Science. 2010;328:137.
   PubMed Web of Science ®Google Scholar
• Behrman RE, Woodcock J. FDA regulations for drug development. Science. 2010;329:33.
   PubMed Web of Science ®Google Scholar
• Kim S, Thiessen PA, Bolton EE, et al. PubChem Substance and Compound databases. Nucleic Acids Res. 2016;44(D1):D1202–13.
   PubMed Web of Science ®Google Scholar
• Gilson MK, Liu T, Baitaluk M, et al. BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res. 2016;44(D1):D1045–53.
   PubMed Web of Science ®Google Scholar
• Zhao W, Yang H. Statistical methods in drug combination studies. Boca Raton (FL): A Chapman and Hall/CRC Press; 2014.
   Google Scholar
• Brown L, Donev AN, Bissett AC. General blending models for data from mixture experiments. Technometrics. 2015;57:449–456.
   PubMed Web of Science ®Google Scholar
• Yang H, Novick SJ, Zhao W. Testing drug additivity based on monotherapies. Pharm Stat. 2015;14:332–340.
   PubMed Web of Science ®Google Scholar
• Dressman JB, Thelen K, Willmann S. An update on computational oral absorption simulation. Expert Opin Drug Metab Toxicol. 2011;7(11):1345–1364.
   PubMed Web of Science ®Google Scholar
• Paixão P, Gouveia LF, Morais JA. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model. Int J Pharm. 2012;429:84–98.
   PubMed Web of Science ®Google Scholar
• Sjögren E, Westergren J, Grant I, et al. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur J Pharm Sci. 2013;49:679–698.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:1639–1650.
   PubMed Web of Science ®Google Scholar
• Afzal S, Gusella M, Vainer B, et al. Combinations of polymorphisms in genes involved in the 5-fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin Cancer Res. 2011;17:3822–3829.
   PubMed Web of Science ®Google Scholar
• Komura T, Miura K, Shirasaka T, et al. Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects. Int J Clin Oncol. 2015;20(1):117–125.
   PubMed Web of Science ®Google Scholar
• Lipkin M, Sherlock P, Bell B. Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon, and rectum. Gastroenterology. 1963;45:721–729.
   PubMed Web of Science ®Google Scholar
• Clarkson B, Ota K, Ohkita T, et al. Kinetics of proliferation of cancer cells in neoplastic effusions in man. Cancer. 1965;18:1189–1213.
   PubMed Web of Science ®Google Scholar
• Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009;39:2–15.
   PubMed Web of Science ®Google Scholar
• Arai W, Hosoya Y, Haruta H, et al. Comparison of alternate-day versus consecutive-day treatment with S-1 assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo. Int J Clin Oncol. 2008;13:515–520.
   PubMed Web of Science ®Google Scholar
• Kajiwara T, Miura K, Ohnuma S, et al. Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration. Int J Clin Oncol. 2015;20:913–921.
   PubMed Web of Science ®Google Scholar
• Brown EM, Sadarangani M, Finlay BB. The role of the immune system in governing host-microbe interactions in the intestine. Nat Immunol. 2013;14:660–667.
   PubMed Web of Science ®Google Scholar
• Karin M, Jobin C, Balkwill F. Chemotherapy, immunity and microbiota – a new triumvirate?. Nat Med. 2014;20:126–127.
   PubMed Web of Science ®Google Scholar
• Vanlancker E, Vanhoecke B, Smet R, et al. 5-Fluorouracil sensitivity varies among oral microorganisms. J Med Microbiol. 2016;65:775–783.
   PubMed Web of Science ®Google Scholar